Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong
Managing Director & CEO, Leslie Chong
Source: Imugene
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Imugene (IMU) has begun dosing the second cohort of patients in the phase one clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx
  • The study in patients with non-small cell lung cancer is assessing three different doses of the possible treatment
  • The primary objective is to determine the optimal dosing of PD1-Vaxx as a monotherapy but will also measure efficacy, tolerability and immune response
  • The study was able to progress to the mid-dose cohort after the review committee found the immunotherapy candidate was safe with no dose-limiting adverse reactions in the first cohort
  • Shares have been trading 5 per cent higher at 10.5 cents

Imugene (IMU) has begun dosing the second cohort of patients in the phase one clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx.

The first-in-human, multi-centre trial in patients with non-small cell lung cancer is assessing three different doses of the possible treatment.

The primary objective is to determine the optimal dosing of PD1-Vaxx as a monotherapy but will also measure efficacy, tolerability and immune response.

“The start of our Food and Drug Administration (FDA) investigational new drug (IND) approved clinical trial formally in the U.S., the largest pharmaceutical market globally, is a significant milestone for Imugene,” said Imugene Managing Director and CEO Leslie Chong.

The first patient in the mid-dose cohort was dosed with the immunotherapy candidate at the Hackensack University Medical Center in New Jersey.

Progression to the mid-dose cohort follows approval from the Dosing Review Committee which determined PD1-Vaxx was safe with no dose-limiting adverse reactions.

PD1-Vaxx is a B-cell cancer immunotherapy and was designed to treat tumors by interfering with PD-1/PD-L1 binding and interaction and producing an anti-cancer effect.

Shares have been trading 5 per cent higher at 10.5 cents at 10:14 am AEDT.

imu by the numbers
More From The Market Online

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…

TruScreen continues global growth with product registration in Kenya

TruScreen Group has received product registration in the Republic of Kenya, a priority market for cervical…

Artrya expands US commercial momentum with five-year HonorHealth agreement

Atrya has signed a five-year commercial agreement with major Arizona health system HonorHealth and becomes fifth…